Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of…
<!-- Name:DistributionId Value:8810786 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
Revive Therapeutics Ltd.
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
<!-- Name:DistributionId Value:8743095 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of…
<!-- Name:DistributionId Value:8742224 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden…
TORONTO (Kanada), Jan. 13, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. („Revive“ oder das „Unternehmen“) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), ein spezialisiertes Biowissenschaftsunternehmen, das sich auf die Erforschung und…
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted…
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for…
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron…
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for…
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol…
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for…
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of…
Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use…
TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for…
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for…